Pharmacovigilance guidelines of Chinese patent medicines
Drug administration law of the People's Republic of China(2019 revised edition),which came into effect on December 1,2019,proposed that"the state shall establish a pharmacovigilance system".Pharmacovigilance work of Chinese patent medicines is more difficult,and it is necessary to carry out Pharmacovigilance activities that are in line with the characteristics of Chinese patent medicines.Pharmacovigilance guidelines of Chinese patent medicines(T/CACM 1563.1-2024),based on the principles of Drug Administration Law of the People's Republic of China(2019 revised edition)and Pharmacovigilance quality management standards(No.65 of 2021)of the National Medical Products Administration,draws on the EU Pharmacovigilance regulation and the secondary guidelines of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH),and it is drafted in accordance with the provisions of Guidelines for standardization work part 1:structure and drafting rules of standardization documents(GB/T1.1-2020)based on the characteristics of Chinese patent medicines.It serves as a general document for a series of pharmacovigilance guidelines of Chinese patent medicines,such as Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions(T/CACM 1563.2-2024),Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines(T/CACM 1563.3-2024),Pharmacovigilance guidelines for clinical application of traditional Chinese medicine injections(T/CACM 1563.4-2024),Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use(T/CACM 1563.5-2024),and Pharmacovigilance guidelines for clinical application of Chinese patent medicines for mucosal administration(T/CACM 1563.6-2024),including four major elements of pharmacovigilance monitoring and reporting of Chinese patent medicines,signal identification,risk evaluation,and risk control,as well as pharmacovigilance activities for Chinese patent medicines,ensuring the safety of public drug use.
Chinese patent medicinepharmacovigilancegroup standardguidelinesafe drug use
NETL
NSTL
万方数据
